par Ukwishaka, Joyeuse;Mela, Cyril Fotabong;Aseneh, Jerry Brown Njoh;Ettaj, Malak;Ilboudo, Dieudonné
;Danwang, Celestin;Samadoulougou, Sékou;Kirakoya, Fati 
Référence BMC public health, 24, 1, page (2925)
Publication Publié, 2024-10


Référence BMC public health, 24, 1, page (2925)
Publication Publié, 2024-10
Article révisé par les pairs
Résumé : | The development of a potent immune response and antibodies against SARS-CoV-2 is important for herd immunity. The serological response may be due to a previous infection or vaccination. Healthy blood donors could represent and provide information on the immune status of the general population. Therefore, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy blood donors. |